Filing Flows › Companies › Usana Health Sciences › Timeline
Usana Health Sciences stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−28.9% to $13.63
Usana Health Sciences (USNA) stock fell 29% over the last 252 sessions, to $13.63. On the way it reported 4 quarters, its insiders filed 15 open-market trades, and the company filed 3 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 3, 2026 | Earnings | Earnings: missed the EPS estimate by -200.0% | +1.0% (+0.7% vs SPY) | — | — |
| Oct 5, 2026 | 8-K | Material definitive agreement | −0.1% (−0.7% vs SPY) | +0.7% (+0.3% vs SPY) | +0.1% (+2.8% vs SPY) |
| Aug 4, 2026 | Earnings | Earnings: missed the EPS estimate by -116.3% | −0.3% (−2.1% vs SPY) | −46.5% (−48.6% vs SPY) | −49.2% (−49.8% vs SPY) |
| Jun 16, 2026 | Insider sale | Neidig Brent sold $97K | −2.1% (−1.5% vs SPY) | −1.1% (+1.5% vs SPY) | +15.5% (+15.8% vs SPY) |
| Jun 15, 2026 | Insider sale | Neidig Brent sold $18K | −2.5% (−4.3% vs SPY) | −5.2% (−5.8% vs SPY) | +11.4% (+9.4% vs SPY) |
| Jun 12, 2026 | Insider sale | Neidig Brent sold $32K | +0.2% (−0.3% vs SPY) | −5.1% (−6.6% vs SPY) | +7.4% (+5.3% vs SPY) |
| Jun 8, 2026 | Insider sale | Jones Paul A. sold $103K | +3.7% (+3.4% vs SPY) | +9.9% (+9.3% vs SPY) | +16.1% (+14.8% vs SPY) |
| Jun 1, 2026 | Insider sale | Fleming John Turman sold $44K | +0.2% (−0.1% vs SPY) | −1.5% (+1.0% vs SPY) | +15.4% (+16.5% vs SPY) |
| May 28, 2026 | Insider sale | Jones Paul A. sold $129K | +0.2% (−0.3% vs SPY) | −7.4% (−7.9% vs SPY) | +9.6% (+12.3% vs SPY) |
| May 27, 2026 | Insider sale | Iiekking G Doug sold $100K | +2.9% (+2.9% vs SPY) | −1.2% (−2.4% vs SPY) | +7.5% (+9.4% vs SPY) |
| May 22, 2026 | Insider sale | Fuller Gilbert A sold $20K | +1.0% (+0.6% vs SPY) | −1.4% (−3.2% vs SPY) | +3.4% (+4.4% vs SPY) |
| May 7, 2026 | Insider sale | Foukas Joshua sold $75K | −2.8% (−2.5% vs SPY) | −12.8% (−13.9% vs SPY) | −10.4% (−10.9% vs SPY) |
| May 5, 2026 | Earnings | Earnings: beat the EPS estimate by 38.6% | +3.7% (+2.9% vs SPY) | −6.3% (−9.2% vs SPY) | −6.1% (−11.0% vs SPY) |
| Mar 20, 2026 | Insider sale | Fuller Gilbert A sold $18K | −1.3% (+0.1% vs SPY) | +0.8% (+2.8% vs SPY) | +18.6% (+11.1% vs SPY) |
| Mar 3, 2026 | Insider sale | Benedict Peter sold $88K | −3.2% (−2.3% vs SPY) | −12.9% (−11.7% vs SPY) | −14.0% (−8.8% vs SPY) |
| Feb 20, 2026 | Insider sale | Foukas Joshua sold $95K | +5.3% (+4.6% vs SPY) | +2.9% (+2.2% vs SPY) | −19.5% (−14.3% vs SPY) |
| Feb 17, 2026 | Earnings | Earnings: beat the EPS estimate by 46.3% | −1.1% (−1.3% vs SPY) | +4.3% (+4.2% vs SPY) | −16.8% (−15.2% vs SPY) |
| Feb 11, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.9% (+0.7% vs SPY) | −2.8% (−1.8% vs SPY) | −19.8% (−15.4% vs SPY) |
| Jan 8, 2026 | 8-K | Directors and officers: departures, appointments, pay | +2.2% (+2.2% vs SPY) | +4.5% (+4.4% vs SPY) | +8.7% (+8.5% vs SPY) |
| Dec 10, 2025 | Insider sale | Mulham David Mulham sold $18K | +4.0% (+3.3% vs SPY) | +1.3% (+1.9% vs SPY) | −1.1% (−3.0% vs SPY) |
| Dec 10, 2025 | Insider sale | Benedict Peter sold $56K | +4.0% (+3.3% vs SPY) | +1.3% (+1.9% vs SPY) | −1.1% (−3.0% vs SPY) |
| Nov 10, 2025 | Insider sale | Winssinger Frederic J sold $38K | +0.3% (−1.3% vs SPY) | +0.3% (+0.2% vs SPY) | +4.8% (+3.0% vs SPY) |
Insiders’ record here
In the year on the chart, Usana Health Sciences' insiders reported 0 open-market buys ($0) and 15 sales ($933K). Of the 15 old enough to score, 14 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −23.1%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Usana Health Sciences: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.